Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05395052 · ClinicalTrials.gov registry record · Phase 1
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05395052: Clinical Trial Phase 1 study, sponsored by Fate Therapeutics.
NCT05395052 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05395052, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Primary Outcome
The RP2Ds of FT536 monotherapy and FT536 + monoclonal antibody (mAbs) will be determined. The RP2D will be determined based on the overall safety and efficacy profile.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG IL-2
- DRUG FT536
- COMBINATION_PRODUCT Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Why NCT05395052 stopped before completion
NCT05395052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05395052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05395052 about?
NCT05395052 is a clinical study titled "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors". This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific co...
What is the current status of trial NCT05395052?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-05-31. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT05395052?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IL-2 (DRUG), FT536 (DRUG), Avelumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05395052?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05395052's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI